184 related articles for article (PubMed ID: 29341832)
1. Racial Differences in 21-Gene Recurrence Scores Among Patients With Hormone Receptor-Positive, Node-Negative Breast Cancer.
Holowatyj AN; Cote ML; Ruterbusch JJ; Ghanem K; Schwartz AG; Vigneau FD; Gorski DH; Purrington KS
J Clin Oncol; 2018 Mar; 36(7):652-658. PubMed ID: 29341832
[TBL] [Abstract][Full Text] [Related]
2. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
Partin JF; Mamounas EP
Ann Surg Oncol; 2011 Nov; 18(12):3399-406. PubMed ID: 21537874
[TBL] [Abstract][Full Text] [Related]
3. [Impact of the 21-gene recurrence score assay in clinical treatment and prognosis analysis for patients with hormone receptor positive early-stage breast cancer].
Zhang YN; Zhou YD; Mao F; Guan JH; Lin Y; Wang XJ; Shen SJ; Wang CJ; Yao R; Sun Q
Zhonghua Zhong Liu Za Zhi; 2018 Feb; 40(2):110-114. PubMed ID: 29502370
[No Abstract] [Full Text] [Related]
4. Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer.
Poorvu PD; Gelber SI; Rosenberg SM; Ruddy KJ; Tamimi RM; Collins LC; Peppercorn J; Schapira L; Borges VF; Come SE; Warner E; Jakubowski DM; Russell C; Winer EP; Partridge AH
J Clin Oncol; 2020 Mar; 38(7):725-733. PubMed ID: 31809240
[TBL] [Abstract][Full Text] [Related]
5. 21-Gene recurrence scores: racial differences in testing, scores, treatment, and outcome.
Lund MJ; Mosunjac M; Davis KM; Gabram-Mendola S; Rizzo M; Bumpers HL; Hearn S; Zelnak A; Styblo T; O'Regan RM
Cancer; 2012 Feb; 118(3):788-96. PubMed ID: 21720988
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of 21-gene recurrence score assay for hormone receptor-positive, lymph node-negative breast cancer in early stage.
Yu-Qing Y; Lei W; Mei-Ling H; Jing-Jing X; Mei-Chen W; Jiang W; Jun-Sheng H; Rui L; Nan-Lin L
Exp Mol Pathol; 2019 Jun; 108():150-155. PubMed ID: 31026440
[TBL] [Abstract][Full Text] [Related]
7. 21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy.
Mamounas EP; Liu Q; Paik S; Baehner FL; Tang G; Jeong JH; Kim SR; Butler SM; Jamshidian F; Cherbavaz DB; Sing AP; Shak S; Julian TB; Lembersky BC; Wickerham DL; Costantino JP; Wolmark N
J Natl Cancer Inst; 2017 Jan; 109(4):. PubMed ID: 28122895
[TBL] [Abstract][Full Text] [Related]
8. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller.
Gonzalez-Angulo AM; Litton JK; Broglio KR; Meric-Bernstam F; Rakkhit R; Cardoso F; Peintinger F; Hanrahan EO; Sahin A; Guray M; Larsimont D; Feoli F; Stranzl H; Buchholz TA; Valero V; Theriault R; Piccart-Gebhart M; Ravdin PM; Berry DA; Hortobagyi GN
J Clin Oncol; 2009 Dec; 27(34):5700-6. PubMed ID: 19884543
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Oncotype DX Recurrence Score as a prognostic factor in Japanese women with estrogen receptor-positive, node-negative primary Stage I or IIA breast cancer.
Yorozuya K; Takeuchi T; Yoshida M; Mouri Y; Kousaka J; Fujii K; Nakano S; Fukutomi T; Hara K; Ichihara S; Lin Y; Kikuchi S
J Cancer Res Clin Oncol; 2010 Jun; 136(6):939-44. PubMed ID: 19946706
[TBL] [Abstract][Full Text] [Related]
10. The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).
Penault-Llorca F; Filleron T; Asselain B; Baehner FL; Fumoleau P; Lacroix-Triki M; Anderson JM; Yoshizawa C; Cherbavaz DB; Shak S; Roca L; Sagan C; Lemonnier J; Martin AL; Roché H
BMC Cancer; 2018 May; 18(1):526. PubMed ID: 29728098
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant chemotherapy and survival among patients 70 years of age and younger with node-negative breast cancer and the 21-gene recurrence score of 26-30.
Park S; Han Y; Liu Y; Toriola AT; Peterson LL; Colditz GA; Kim SI; Cho YU; Park BW; Park Y
Breast Cancer Res; 2019 Oct; 21(1):110. PubMed ID: 31619259
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiling for breast cancer prognosis in Chinese populations.
Sun B; Zhang F; Wu SK; Guo X; Zhang LL; Jiang ZF; Wang DM; Song ST
Breast J; 2011; 17(2):172-9. PubMed ID: 21410584
[TBL] [Abstract][Full Text] [Related]
13. Uptake of the 21-Gene Assay Among Women With Node-Positive, Hormone Receptor-Positive Breast Cancer.
Roberts MC; Kurian AW; Petkov VI
J Natl Compr Canc Netw; 2019 Jun; 17(6):662-668. PubMed ID: 31200352
[TBL] [Abstract][Full Text] [Related]
14. Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial.
Albain KS; Gray RJ; Makower DF; Faghih A; Hayes DF; Geyer CE; Dees EC; Goetz MP; Olson JA; Lively T; Badve SS; Saphner TJ; Wagner LI; Whelan TJ; Ellis MJ; Wood WC; Keane MM; Gomez HL; Reddy PS; Goggins TF; Mayer IA; Brufsky AM; Toppmeyer DL; Kaklamani VG; Berenberg JL; Abrams J; Sledge GW; Sparano JA
J Natl Cancer Inst; 2021 Apr; 113(4):390-399. PubMed ID: 32986828
[TBL] [Abstract][Full Text] [Related]
15. Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up.
Wen HY; Krystel-Whittemore M; Patil S; Pareja F; Bowser ZL; Dickler MN; Norton L; Morrow M; Hudis CA; Brogi E
Cancer; 2017 Jan; 123(1):131-137. PubMed ID: 27526056
[TBL] [Abstract][Full Text] [Related]
16. Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results.
Press DJ; Ibraheem A; Dolan ME; Goss KH; Conzen S; Huo D
Breast Cancer Res Treat; 2018 Feb; 168(1):207-220. PubMed ID: 29181717
[TBL] [Abstract][Full Text] [Related]
17. Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study.
Dieci MV; Guarneri V; Zustovich F; Mion M; Morandi P; Bria E; Merlini L; Bullian P; Oliani C; Gori S; Giarratano T; Orvieto E; Griguolo G; Michieletto S; Saibene T; Del Bianco P; De Salvo GL; Conte P;
Oncologist; 2019 Nov; 24(11):1424-1431. PubMed ID: 31152079
[TBL] [Abstract][Full Text] [Related]
18. Prognostic features of breast cancer differ between women in the Democratic Republic of Congo and Belgium.
Luyeye Mvila G; Batalansi D; Praet M; Marchal G; Laenen A; Christiaens MR; Brouckaert O; Ali-Risasi C; Neven P; Van Ongeval C
Breast; 2015 Oct; 24(5):642-8. PubMed ID: 26279132
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of Hormone-Receptor Positive, HER2-Negative Breast Cancers by Race and Tumor Biological Features.
Benefield HC; Reeder-Hayes KE; Nichols HB; Calhoun BC; Love MI; Kirk EL; Geradts J; Hoadley KA; Cole SR; Earp HS; Olshan AF; Carey LA; Perou CM; Troester MA
JNCI Cancer Spectr; 2021 Feb; 5(1):. PubMed ID: 33442657
[TBL] [Abstract][Full Text] [Related]
20. Molecular Characterization and Mortality From Breast Cancer in Men.
Massarweh SA; Sledge GW; Miller DP; McCullough D; Petkov VI; Shak S
J Clin Oncol; 2018 May; 36(14):1396-1404. PubMed ID: 29584547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
